Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the Oncolytic Virotherapy Summit; Company Will Also Share Progress With Cell-based Virotherapy Platforms For Advanced Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics presented a clinical study for NeuroNova in treating recurrent high-grade glioma at the Oncolytic Virotherapy Summit. The company also shared updates on its cell-based virotherapy platforms for advanced solid tumors.
December 13, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calidi Biotherapeutics' presentation at the Oncolytic Virotherapy Summit regarding NeuroNova and its virotherapy platforms could positively influence investor perception and potential partnerships.
Presenting clinical study results at a summit can often lead to increased visibility and credibility within the medical and investment communities. Positive data can attract potential partnerships and funding, which may lead to an uptick in stock price in the short term.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80